Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.

Diana Canto-Sims, OD, and Raphael Rostenne

October 21st, 2026

The Independent Advantage S02 E07: Is your front desk missing opportunities?

Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.

Clinical trial | Image Credit: Adobe Stock/Puwasit Inyavileart

October 20th, 2026

Duravyu for wet AMD misses primary end point in phase 3 LUCIA trial

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Brytly redness relief drops | Image Credit: Alcon, Inc.

October 19th, 2026

FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours

Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.

October 19th, 2026

Missed AAOpt 2026? Here are the highlights by specialty

From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.

Alice Epitropoulos, MD, FACS, and John Hovanesian, MD

October 16th, 2026

FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.